ALDH1A1缺失诱导主动脉瓣钙化且可被RARα激动剂预防
该临床前研究通过人瓣膜间质细胞转录组分析发现,钙化瓣膜中ALDH1A1表达下调,TGF-β通过SMAD2/3依赖方式抑制其表达;ALDH1A1抑制通过降低视黄酸受体α信号促进成骨样表型和钙沉积。全反式维甲酸在体外和两种动物模型中抑制钙化,并改善异种移植羊模型的超声参数。
要点
- 钙化主动脉瓣的瓣膜间质细胞中ALDH1A1表达显著下调,是转录组分析中最下调的基因。
- ALDH1A1下调通过抑制视黄酸受体α信号促进瓣膜间质细胞成骨样转化和钙沉积。
- 全反式维甲酸在体外和动物模型中抑制主动脉瓣及生物瓣钙化。
核心结论
- ALDH1A1在钙化瓣膜中下调,促进瓣膜间质细胞向成骨样表型转化。
- 视黄酸受体α激动剂(包括全反式维甲酸)是预防自体主动脉瓣和生物瓣钙化的有前景的药物重定位策略。
研究设计与样本
- 比较钙化(二叶式和三叶式)与对照瓣膜来源的瓣膜间质细胞的转录组分析,并收集患者和器官捐献心脏的瓣膜。
- 在对照人主动脉瓣瓣膜间质细胞培养中分析ALDH1A1抑制或沉默对成骨标志物表达和钙化的影响。
- 在两种动物模型中测试全反式维甲酸对钙化的效果:大鼠皮下植入牛心包模型和幼羊异种移植主动脉瓣置换模型。
主要发现
- 转录组分析鉴定ALDH1A1为钙化瓣膜来源瓣膜间质细胞中下调最显著的基因。
- 在人瓣膜间质细胞中,TGF-β通过SMAD2/3依赖方式下调ALDH1A1表达。
- ALDH1A1抑制通过抑制视黄酸受体α信号促进成骨样瓣膜间质细胞表型并增加钙沉积。
- 维甲酸类处理降低瓣膜间质细胞钙沉积并减弱其成骨活性。
- 全反式维甲酸在两种体内模型中抑制主动脉生物瓣钙化,并改善异种移植羊模型的主动脉瓣超声心动图参数。
临床怎么用
- 视黄酸受体α激动剂(如全反式维甲酸)可能作为药物重定位候选,用于预防自体主动脉瓣和生物瓣的纤维钙化进程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, the only effective treatment of severe aortic stenosis is valve replacement. With the introduction of transcatheter aortic valve replacement and extending indications to younger patients, the use of bioprosthetic valves (BPVs) has considerably increased. The main inconvenience of BPVs is their limited durability because of mechanisms similar as the fibro-calcifying processes observed in native aortic stenosis. One of the major gaps of the field is to identify therapeutic targets to prevent or slow the fibro-calcifying process leading to severe and symptomatic aortic stenosis. METHODS: Explanted valves were collected from patients and organ donor hearts. A comparative transcriptomic analysis was performed on valvular interstitial cells (VIC) obtained from calcified (bicuspid and tricuspid) versus control valves. The mechanisms and consequences of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) downregulation were analyzed in VIC cultures from control human aortic valves. ALDH1A1 was inhibited or silenced and its impact on osteogenic marker expression and calcification processes assessed in VIC. The effect of all-trans retinoic acid on calcification was tested on human VIC cultures and on 2 animal models: the model of subcutaneous implantation of bovine pericardium in rats and the model of xenograft aortic valve replacement in juvenile sheep. RESULTS: Transcriptome analysis of human VIC identified ALDH1A1 as the most downregulated gene in VIC from calcified versus control valves. In human VIC, ALDH1A1 expression is downregulated by TGF-β in a SMAD2/3-dependent manner. ALDH1A1 inhibition promotes an osteoblast-like VIC phenotype and increases calcium deposition through inhibition of retinoic acid receptor alpha signaling. Conversely, VIC treatment with retinoids decreases calcium deposition and attenuates VIC osteoblast activity. Last, all-trans retinoic acid inhibits calcification development of aortic BPV in both in vivo models and improves aortic valve echocardiographic parameters in the xenograft sheep model. CONCLUSIONS: These results show that ALDH1A1 is downregulated in calcified valves, hence promoting VIC transition into an osteoblastic phenotype. Retinoic acid receptor alpha agonists, including all-trans retinoic acid through a drug repositioning strategy, represent a promising and innovative pharmacological approach to prevent calcification of native aortic valves and BPV.
引用
- Rosa M, Dupont A, Smadja DM, et al. Aortic Valve Calcification Is Induced by the Loss of ALDH1A1 and Can Be Prevented by Agonists of Retinoic Acid Receptor Alpha: Preclinical Evidence for Drug Repositioning. Circulation. 2025. PMID: 39989358. doi:10.1161/CIRCULATIONAHA.124.071954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。